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Mesenchymal stem cells (MSCs) are the most promising seed cells for cell therapy and can be isolated from various sources of
human adult tissues such as bone marrow (BM-MSC) and adipose tissue. However, cells from these tissues must be obtained
through invasive procedures. We, therefore, characterized MSCs isolated from fresh placenta (Pl-MSC) and fetal membrane (Mb-
MSC) through morphological and ﬂuorescent-activated cell sorting (FACS). MSC frequency is higher in membrane than placenta
(2.14% ± 0.65 versus 15.67% ± 0.29%). Pl/Mb-MSCs in vitro expansion potential was signiﬁcantly higher than BM-MSCs. We
demonstrated that one of the MSC-speciﬁc marker is suﬃcient for MSC isolation and that culture in speciﬁc media is the optimal
way for selecting very homogenous MSC population. These MSCs could be diﬀerentiated into mesodermal cells expressing cell
markers and cytologic staining consistent with mature osteoblasts and adipocytes. Transcriptomic analysis and cytokine arrays
demonstrated broad similarity between placenta- and membrane-derived MSCs and only discrete diﬀerences with BM-MSCs with
enrichment of networks involved in bone diﬀerentiation. Pl/Mb-MSCs displayed higher osteogenic diﬀerentiation potential than
BM-MSC when their response to osteoactivin was evaluated. Fetal-tissue-derived mesenchymal cells may, therefore, be considered
as a major source of MSCs to reach clinical scale banking in particular for bone regeneration.
1.Introduction
Multipotent mesenchymal stem cells (MSCs) are able to self-
renewed and diﬀerentiate into mesodermal lineages such
as adipogenic, chondrogenic, osteogenic, myogenic, and
angiogenic cells [1]. MSCs were initially isolated from bone
marrow by Haynesworth et al. [2]. In the bone marrow,
theyprovidesupportforhematopoiesis[3].Theyalsosecrete
several growth factors important in angiogenesis including
vascular endothelial growth factors [4]. Therefore, they rep-
resent one of the most promising cell types for cell therapies
and tissue engineering or trauma repair. Indeed, diﬀerent
preclinical experiments using MSCs have been performed
demonstrating their ability to improve myocardial or cere-
bral function after ischemic stress, or liver and joint damage
after traumatic or surgical injuries [5–8]. They might also be
optimal for cellular therapy by inducing immune tolerance.
Indeed, they can generally be transplanted even in large
outbreed animals across major histocompatibility complex
(MHC) barriers without need for immune suppression [9].
The bone marrow is the traditional source of human
MSCs, but they have been isolated from a wide variety of
human adult tissues such as adipose tissue [10], lung [11],
and liver [12]. However, cells from most of these tissues must2 Stem Cells International
be obtained through invasive procedures, and the interindi-
vidual variability is hard to control. Several studies describe
the isolations of MSCs from fetal tissues such as umbilical
cord blood [13], placenta [14–16], amniotic membrane [17,
18], and amniotic ﬂuid [19], and they have described their
MSCs characteristics.
Osteoactivin (OA) has the ability to regulate cell prolifer-
ation,adhesion,diﬀerentiation,andsynthesisofextracellular
matrix proteins in various cell types [20–30]. OA messen-
ger ribonucleic acid (mRNA) and protein are expressed
by human and rodent osteoblasts [29, 30]. OA down-
regulation decreases osteoblast diﬀerentiation and function
[31]. Osteoblast cells express increasing levels of OA protein
during their diﬀerentiation. OA has been demonstrated as
essential for the diﬀerentiation and functioning of osteoblast
cells [32]. We previously demonstrated that OA induces sim-
ilarosteoblasticdiﬀer entiationthanBMP2inmic eMSCsug-
gesting that OA may be a novel osteoinductive agent [29, 31,
32].
In this study, we optimized the isolation of placental and
amniotic membrane MSC and compared their proliferative
and diﬀerentiation potential to BM-MSCs. We isolated
through diﬀerent methods MSCs from placenta and fetal
membranes, and we qualiﬁed them according to the stan-
dardize protocols from the international society for cellular
therapy (ISCT) [33]. We further investigated and demon-
stratedthatOAtriggersosteoblasticdiﬀerentiationinhuman
MSCs and that the diﬀerentiation was even more important
i nf e t a lM S C sa sc o m p a r e dt oB M - M S C s .W ei l l u s t r a t et h a t
fetal tissues derived MSCs are more prone than BM-MSCs to
diﬀerentiate into osteoblasts.
2.MaterialsandMethods
2.1. Placenta and Fetal Membranes Collection. Following ap-
proval from the Internal Review Board (HMC-IRB Protocol
9109/09, Weill Cornell Medical College in Qatar), placen-
tas and fetal membranes were collected from donors at
Woman’s Hospital at Hamad Medical Corporation immedi-
ately after elective caesarean section at term in the absence
of labor, preterm rupture of membrane, chorioamnionitis,
preeclampsia, intrauterine growth retardation, or chromo-
somal abnormalities. The specimen were completely dei-
dentiﬁed and considered as biological waste. Therefore, no
consent form was taken from the patients.
2.2. Mesenchymal Stem Cell Isolation. Supplementary
Figure 1 (available at doi:10.1155/2012/658356) depicts the
isolation procedures used in this study. For placenta, the
decidua basalis was removed prior to harvesting the
placental tissues. The placenta parts were free of any fetal
membrane. For fetal membrane, we decided not to separate
the amnion and chorion parts to illustrate the most direct
workﬂow for MSCs isolation. The harvested pieces of
tissues were washed in phosphate buﬀer saline (PBS, PH
7.4), mechanically minced into pieces of approximately
1mm 2, and subsequently digested with dispase (1mg/mL,
Hyclone), collagenase(300U/mL) (Hyclone), hyalluronidase
(100U/mL, Hyclone), and DNAse I (80U/mL, Roche) for
1hat37 ◦C under agitation (150rpm). The homogenate was
subsequently washed in PBS. Cells were then ﬁltered on a
100μm cells strainer. Red blood cells and aggregates were
eliminated on a Ficoll gradient. The mononucleated fraction
was collected for further analysis.
Two million viable cells were then either directly plated
in MSCs culture media (DMEM low glucose with 20% FBS,
2mM L-Glutamin, and 1% penicillin/streptomycin [16]) or
sorted through SORP FACS Aria II (BD Biosciences) and
then plated in the MSC culture media in 24 well plates.
Cultures were incubated in humidiﬁed 5% CO2 incubators
and the media was replaced every 3 days.
Several bone marrows MSCs from diﬀerent donors
(BM-MSCs) were purchased from Stem Cell Inc. (number
MSC-001F, Stem Cell Inc.) and PromoCell (number 12974,
PromoCell) and maintained in the same culture conditions
as placenta-/membrane-derived MSCs (Pl/Mb-MSCs). We
performed all analysis at the 4th passages in order to obtain
a homogenous cell population and suﬃcient number of cells
to perform all analysis in parallel.
2.3. Immunostaining and Fluorescence-Activated Cell Sorting
(FACS) Analysis. For ﬂow analysis of cell surface antigens
and cell sorting, MSCs were stained for the expression
of CD45, CD34, CD73, CD105, CD90, and CD29 using
Mouse anti-human CD45 antibody (BD Biosciences, num-
ber 339192, clone 2D1) coupled with Amcyan, Mouse anti-
human CD34 (BD Biosciences, number 555821, clone 581)
coupled with FITC, Mouse anti-human CD105 (biolegend,
number 323212, clone 43A3) coupled with AF647, Mouse
anti-human CD73 (BD Biosciences, number 550257, clone
AD2) coupled with PE, Mouse anti-human CD29 (biole-
gend, number 323212, clone TS2/16) coupled with APC-
Cy7,andMouseanti-humanCD90(BDBiosciences,number
550402, clone 5E10) coupled with AF700.
Brieﬂy, 1.106 cells were harvested and nonspeciﬁc sites
were blocked in PBS-5%FBS-1%BSA-10%FcR Blocking
Reagent(MyltenyiBiotec)for30minutesonice.Cellsuspen-
sion was incubated with speciﬁc antibodies for 45 minutes
on ice. After washes in PBS and ﬁltration on 45μm strainer,
cells were analyzed by ﬂuorescence activated-cell sorting
(FACS)onaSORPFACSAriaII(BDBiosciences)asdescribed
later. Data were processed with FACSDiva 6.3 software (BD
Biosciences). Doublets were excluded by FSC-W × FSC-H
and SSC-W × SSC-H analyses, single-stained channels were
used for compensation, and ﬂuorophore minus one (FMO)
controls were used for gating, 500000 events were acquired
per sample [34].
2.4. Immunocytochemistry. Cells in culture were grown on 8
chamber slides (BD falcon, number 354102) and stained as
follows.
The antibodies used were Mouse anti-human CD29-
FITC (biolegend, number 303016, clone TS2/16), CD73-PE
(BD Biosciences, number 550257, clone AD2), CD90-AF568
(BD Biosciences, number 550402, clone 5E10), CD34-PEStem Cells International 3
(BDBiosciences,number555822,clone581),CD45-Amcyan
(BDBiosciences,number339192,clone2D1),unconjugated,
and CD105 (BD Biosciences, number 555690, clone 266)
revealed by a secondary goat anti mouse IgG1 antibody
(invitrogen, number A-21121).
Brieﬂy, nonspeciﬁc sites and Fc receptors were blocked
with PBS/0.3% bovine serum albumin/0.5% HS for 30
minutes and FcR blocking reagent (Miltenyi, number 120-
000-442). Sections were incubated with primary antibodies
(1 hour 30 minutes), washed twice in PBS/0.5% Tween
20 (Sigma-Aldrich), and if necessary incubated with sec-
ondary antibodies (1 hour, AF488 goat anti-mouse IgG1 at
0.5μg/mL). Nuclei were counterstained with 4-,6-diamidi-
no-2-phenylindole (Invitrogen). Slides were mounted with
the Fluoromount Kit (Invitrogen). Sections were analyzed
with a Zeiss confocal microscope Laser Scanning Microscope
710 (Carl Zeiss). Pictures were analyzed with Zen 2008
V5,0,0228 software (Carl Zeiss).
2.5. Mesodermal Lineage Diﬀerentiation
2.5.1. Adipogenic Lineage. Adipogenic diﬀerentiation was
induced by culturing 80% conﬂuent MSC for 3 weeks in
DMEM-HG,1μMdexamethasone,5μg/mLinsulin(Sigma),
60μM indomethacin (Sigma; catalogue number: 17378-5G),
and 0.5mM 3-Isobutyl-1-methylxanthine (IBMX; Sigma;
catalogue number: I5879) [35]. Adipogenic diﬀerentiation
was assessed by staining cells in wells with Oil Red O.
2.5.2. Osteogenic Lineage. Osteogenic diﬀerentiation was
induced by culturing 90% conﬂuent MSC for 3 weeks
in DMEM-LG, 10% FCS, 0.1μM dexamethasone (Sigma;
Australia Register Number: 16375; Melbourne, Victoria,
Australia), 50μM L-ascorbic acid-2-phosphate (Sigma; cat-
alogue number: A8960-5G; Castle Hill, New South Wales,
Australia), 10mM β-glycerol phosphate disodium salt pen-
tahydrate (Sigma; catalogue number: 50020), and 0.3mM
inorganic (sodium) phosphate (Sigma) [35, 36]. Osteogenic
diﬀerentiation was assessed by staining with Alizarin Red S.
2.5.3. Osteoactivin Stimulation. Three days after MSCs plat-
ing (50% conﬂuence), recombinant human osteoactivin was
delivered in a single dose of 100ng/mL in diﬀerentiation
media DMEM-LG, 10% FCS, 0.1μM dexamethasone, 50μM
L-ascorbic acid-2-phosphate, 10mM β-glycerol phosphate
disodium salt pentahydrate, and 0.3mM inorganic (sodium)
phosphate. Controls were carried out in regular cell culture
media described above. The osteogenic diﬀerentiation was
then assessed at day 7, 14, and 21 after OA treatment by
staining with Alizarin Red S. Following treatment, color
phasecontrastmicroscopypictureswereacquiredatdiﬀerent
time points. Analysis of the red channel was performed using
image J (NIH). Normalization for cell number was done
using the blue channel.
2.6. Transcriptomic Analysis. RNA was isolated using Trizol
reagent followed by additional puriﬁcation using RNAeasy
extraction kit from Qiagen (QIAGEN, number 74106) with
RNA yields that produces satisfactory microarray data. Two
quality control measures were carried out: (1) a spectropho-
tometric analysis and (2) a size fractionation procedure
using a microﬂuidics instrument (Agilent Technologies).
200ng of total RNA were analyzed on Aﬀymetrix GeneChip
Human Genome U133 Plus 2.0 Array. Data were analyzed
using Parteck Software (V6.09.1110-6; Aﬃmetrix). Class
comparison between BM-MSCs and Pl/Mb-MSCs (three
biological replicates of each) was performed to identify gene
expression changes with a signiﬁcant expression diﬀerences
(P<0.05) and 2-fold increase or decrease expression.
Parteck Software gene ontology tools were used to determine
gene enrichment [37].
We used Ingenuity Pathway Analysis software (Ingenuity
Systems, Redwood City, CA) to identify and analyze relevant
pathways from the gene lists obtained after comparison of
BM-MSC and Mb/Pl-MSC. Networks were constructed by
overlaying the genes in the gene list onto a global molecular
network developed from information contained in the Inge-
nuity Pathways Knowledge database using keywords such as
organ formation and osteoblast diﬀerentiation. Networks of
the genes up- or downregulated Pl/Mb-MSCs as compared
to BM-MSCs were then algorithmically generated based on
their connectivity. A network is a graphical representation
of the molecular relationships between genes. Genes are
representedasnodes,andthebiologicalrelationshipbetween
two nodes is represented as a line. All edges are supported by
at least one reference from the literature, from a textbook,
or from canonical information stored in the Ingenuity
Pathways knowledge database. P values for the enrichment
of canonical pathways were then generated based on the
hypergeometric distribution and calculated with the right-
tailed Fisher’s exact t-test for 2 × 2 contingency tables.
2.7. Phospho-Kinase Array. MSCs were cultivated in dif-
ferentiation or control media in presence or absence of
OA for 4h. Cells were harvested and proteins extracted as
recommendedandquantiﬁedbasedonsampleabsorbanceat
280nm using nanodrop device (Thermo-Scientiﬁc). 200μg
of protein was loaded on R&D system Human Phospho-
kinase Antibody Array (R&D system, number ARY003)
according to manufacturer’s instructions.
Arrays were revealed using HorseRadish Peroxidase
(HRP) and SuperSignal West Pico Chemiluminescent Sub-
strate (Thermo Scientiﬁc). Data were collected using Geli-
ance CCD camera (Perkin Elmer) and extracted using Image
J software (NIH). Brieﬂy, arrays’ pictures were inverted and
background subtracted. We deﬁned a 120-micron diameter
area for signal capture. Median pixel density was used
to evaluate the signal. For comparison, independent array
values were normalized on their positive control intensity
values.
2.8. Cytokine Array. MSCs were cultivated in serum free
mediafor72hoursaspreviouslypublished[38].Supernatant
was collected and proteins quantiﬁed based on sample
absorbance at 280nm using nanodrop device (Thermo-
Scientiﬁc). 200μg of protein was loaded on R&D system4 Stem Cells International
Human Cytokine Antibody Array panel A (R&D system,
number ARY005) according to manufacturer’s instructions.
Arrays were analyzed as described above.
2.9.StatisticalAnalysis. Student-t,Fisherexact,orchi-square
tests were performed as appropriate. All P-values are two-
sided with statistical signiﬁcance evaluated at the 0.05 alpha
level. All statistical analysis were done using the data analysis
plug-in shipped into the Excel 2008 for Mac (Microsoft). We
ﬁrst calculated the variance of two paired. Mean ± SEM are
shown on the graphs. All results are representative of the
indicated number of independent experiments.
3. Results
3.1. MSCs Isolation Methods. Supplementary Figure 1
depicts the workﬂow chart of the enzyme-mediated cell iso-
lation of human term placenta/membrane, by direct cul-
ture or cell sorting, for derivation of ﬁbroblast-like cells,
that we characterized as multipotent mesenchymal stem
cells (MSCs). Two methods were used to isolate MSCs.
(i) selection in speciﬁc MSC media after direct culture
of cell suspension obtained following tissue digestion, (ii)
ﬂuorescent-activated cell sorting according to expression
of speciﬁc MSCs markers as deﬁned by the international
society for cellular therapy (ISCT, positive for CD105, CD73,
CD90, CD29, and negative for CD45 and CD34) [39]. 15
diﬀerent amniotic membranes and placentas were used in
t h i ss t u d y .W ew e r ea b l et od i ﬀerentiate MSCs from all of
these specimens, all analyses are representative of 3 diﬀerent
samples.
3.2. MSCs Are More Abundant in Membrane Than Placenta.
We quantiﬁed the number of MSCs in fetal membrane and
placenta using polyvariate ﬂow cytometry. CD45−, CD34−
cells were selected and analyzed for the expression of CD105,
CD73,CD90,andCD29.MSCsasdeﬁnedbythese4markers
were signiﬁcantly more abundant in the membrane, Mb-
MSC 15.67% (±0.29%) than the placenta, Pl-MSC 2.14%
(±0.65%, Figure 1(a)).
The same results were found when 2 million cells were
directlyplatedaftertissuedigestion.Thenumberofadherent
cells was signiﬁcantly higher at day 1 in the membrane
compare to the placenta (Figure 1(b)).
3.3. Placenta or Membrane Isolated MSCs Have Greater Prolif-
eration Ability Than Bone Marrow MSCs. Growth kinetic of
Mb-MSCs and Pl-MSCs were compared with BM-MSCs at
the same passage. The proliferation rate of Pl/Mb MSCs was
signiﬁcantly higher than BM-MSCs (Figure 1(c)). Moreover,
Mb-MSCs and Pl-MSCs were expandable up to passage 15
without modiﬁcation of their morphology or proliferation
rate as described in other studies however BM-MSC stopped
proliferating after passages 7 to 8 [14].
3.4. Analysis of Subpopulations Based on CD90 and CD29
Expression. We ﬁrst deﬁned our cell population as being
negative for CD45 and CD34. In all our independent
experiences, the vast majority if not all (85% to 99%) of
CD73+, CD105+ cells was also expressing CD90 and CD29
reachingthecanonicaldeﬁnitionofMSCs[33,39].However,
the number of CD90+, CD29+ cells positive for CD73 and
CD105 was lower ranging from 65% To 85% (Figure 2).
We, therefore, decided to further analyze the populations
characterized by CD90/CD29 expression. We wondered our
ability to derive MSCs from these diﬀerent cell populations.
We sorted 4 subpopulations based on the expression of those
markers: CD90+ CD29+; CD90− CD29+; CD90+ CD29−;
CD90− CD29− in placentas and fetal membranes (Figure 2
and Supplementary Figure 2). We performed all experiences
on 3 independent donors. The purity of the sort was assured
by applying the purity mask and controlling for the purity of
the diﬀerent cell populations sorted.
None of the CD90− CD29− c e l l sw e r ea b l et og r o w
in MSCs media. The CD29− CD90− is actually a very
homogenous population containing mostly CD73− CD105−
cells (Supplementary Figure 2). In contrast, we were able
to derive mesenchymal like cells from the 3 other sorted
subpopulations. This indicates that expression of at least one
of these 2 markers is indispensable for MSCs isolation and
qualiﬁcation.
After 4 passages, the large majority of the cells sorted
expressed CD90 and CD29. (Table 1 and Supplementary
Figure 3). At this stage, the large majority displayed a CD73+
CD105+ proﬁle. We conﬁrmed the expression of all markers
by immunoﬂuorescence staining (Supplementary Figure 4).
3.5. Diﬀerentiation Assay of Placenta and Membrane MSCs.
Speciﬁc induction of adipogenic and osteogenic diﬀerentia-
tion was performed on Mb/Pl MSCs sorted based on CD29
and CD90 expression or directly plated after isolation and
compared to BM-MSCs diﬀerentiation (Figure 3(a)).
Alldiﬀerentcellpopulationsfromplacentaormembrane
regardless of the isolation protocol were identically able to
diﬀerentiateinto adipocytes andosteoblastsconﬁrmingtheir
phenotypic and functional similarity (data not shown).
3.6. Cytokines Secretion of MSCs. Cytokine secretion proﬁle
was highly similar between fetal and BM-MSCs with strong
secretion of GROα (CXCL1), IL-6, IL-8 (CXCL8), MCP-
1 (CCL2), MIF (GIF, DER6), and serpin E1 (PAI-1), see
Figures 3(b) and 3(c). Only discrete diﬀerences were noted,
GROα (CXCL1) secretion by the BM-MSCs was higher than
its expression in the fetal MSCs, whereas the expression of
IL-6 and MCP-1 in the BM-MSCs was comparatively lower
t h a ni nf e t a lM S C s .
3.7. Transcriptomic Comparison of Fetal and Bone Marrow
MSCs. We ﬁrst analyzed diﬀerences between membrane-
derived and placenta-derived MSCs. As demonstrated by our
PCA analysis, MSCs derived from membrane or placenta
could not be diﬀerentiated based upon their transcriptomic
proﬁle (Figure 4(a)). We then analyzed the diﬀerent subpop-
ulations deﬁned by CD90 and CD29 expression. They also
displayed similar transcriptomic proﬁle (Figures 4(b) and
4(c)).Stem Cells International 5
Table 1: Proportion of cell expressing MSCs speciﬁc markers. After 4 passages, every cell sorted subtype and bone marrow MSCs were
stained for CD45, CD34, CD90, CD29, CD105, and CD73. 99% of the cells were CD34 and CD45 negative and more than 80% positive for
the MSCs makers.
CD90+ CD29+ CD105+ CD73+
Bone marrow 97.6% 90.9% 99.7% 98.7%
Membrane 87.6% 99.8% 96.7% 99.8%
Membrane CD29+ CD90+ 79.3% 99.7% 96.4% 99.5%
Membrane CD29+ CD90− 91.8% 98% 98.1% 97.8%
Membrane CD29− CD90+ 85.2% 99.9% 98.5% 99.4%
Placenta 91.1% 99.8% 99.2% 99.5%
Placenta CD29+ CD90+ 79.1% 99.9% 99.1% 99.9%
Placenta CD29− CD90+ 84.7% 99.6% 99.8% 99.5%
When compared to BM-MSCs, 145 genes were signif-
icantly upregulated and 267 genes were downregulated in
Mb-MSCs compared to BM-MSCs (Supplementary Table
1 and Supplementary Figure 5). Similarly, 154 genes were
signiﬁcantly upregulated (133 overlapping with Mb-MSCs
upregulated genes) and 272 genes were downregulated (238
overlapping with Mb-MSCs downregulated genes) in the Pl-
MSCs compared to BM-MSCs (Supplementary Table 2 and
Supplementary Figure 5).
By ingenuity and David analysis, we were able to
deﬁne several pathways and genes implicated in embryonic
morphogenesis and organ development upregulated in the
Pl and Mb-MSC compared to BM-MSC (Figure 4(d) and
Supplementary Table 3). Several genes implicated in extra-
cellularmatrixorganization,theskeletalsystemdevelopment
and vasculature development were upregulated in the BM-
MSC compared to Pl and Mb-MSC (Supplementary Table
4).
We then performed ingenuity pathway analysis building
organ formation and osteoblast diﬀerentiation molecular
networks. We found 14 genes upregulated in Pl/Mb MSC
implicated in osteogenic diﬀerentiation in literature such as
BMP, IGFBP4, IL6, HGF, and PTGS2 (Figure 4(e)).
3.8. Osteoactivin-Derived Osteoblast Diﬀerentiation. Amni-
otic-membrane-derived MSCs (Mb-MSCs) were used for
this part of the study as they are similar to the MSCs derived
from the placenta and more abundant. In our cell culture
and diﬀerentiation settings, the Mb/Pl MSCs displayed no
diﬀerences in their ability to diﬀerentiate toward osteoblasts
compare to BM-MSCs. OA treatment increased the diﬀer-
entiation for both Mb-MSC and BM-MSC at days 14 and
21 as demonstrated by Alizarin red staining, with Mb-MSCs
displaying signiﬁcantly increased osteogenic diﬀerentiation
(Figures 5(a) and 5(b)). We noticed that the addition
of OA to the diﬀerentiation media accelerated osteogenic
diﬀerentiation with positive Alizarin staining from day 7 for
Mb-MSC and day 14 for BM-MSC (data not shown).
3.9. Phosphokinase Array Analysis of Diﬀerentiating Cells.
We analyzed the phosphorylation pattern of a range of
phosphokinase after 4h of OA stimulation in Pl-MSCs
and BM-MSCs (Figures 6(a) and 6(b)). For both cell
lines, there is a phosphorylation of Chk2 compatible with
reduced proliferation during the diﬀerentiation process.
While CREB is phosphorylated in BM-MSC, OA triggers
ERK1/2 phosphorylation in Pl-MSCs. ERK activation was
already previously described by Furochi et al. [40]a s
activated through OA. Those previous ﬁndings together with
our datas lead us to stand for an OA activation role in
osteogenic diﬀerentiation notably through ERK1/2 pathway
activation in fetal-derived MSCs.
4. Discussion
MSCs are thought to have great therapeutic potential due
to their capacity for self-renewal and multilineage diﬀer-
entiation [4, 41]. For example, they support hematopoiesis
and enhance engraftment of hematopoietic stem cells after
cotransplantation [3, 42]. Experimental and clinical data
have demonstrated an immune-regulatory function of BM-
derived MSCs that may contribute to the reduction of
graft-versus-host disease following hematopoietic stem cell
transplantation[43,44].Furthermore,evenifclinicalstudies
remain anecdotal, BM-MSCs have been reported to exert
beneﬁcial eﬀects in the healing of a limited number of
patients with bone nonunions [45–50]. MSCs initiate the
fracturerepairprocessleadingtotheformationofacartilagi-
nous template (callus) that is then replaced by new bone that
ﬁllsthegap[6].LimitationinMSCnumberand/orfunctions
is hypothesized to play a critical role in the pathogenesis of
post fracture nonunions.
Currently, the bone marrow is perceived as the major
source of MSCs for cell therapy. However, aspiration of BM
involves invasive procedures. The frequency, diﬀerentiation,
and growth potential of BM-MSCs decrease signiﬁcantly
with age [51]. Thus, the search for alternative consistent
sources of MSCs is of signiﬁcant value. Indeed, when we
consider therapeutic application, it will be mandatory to
access cell banks displaying a large variety of HLA types.
It has been reported that MSCs could be isolated from
various tissues [11, 52]. Among these sources, placenta and
membrane may be ideal sources due to their accessibility,
painless donor procurement, promising sources for autolo-
gous cell therapy, and lower risk of viral contamination. The6 Stem Cells International
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Figure 1: Higher proportion of MSCs can be isolated from the membrane compare to the placenta. Fetal tissue derived MSCs display
greater proliferation kinetic than bone marrow derived MSCs. (a) MSCs were deﬁned as CD45−,C D 3 4 −,C D 2 9 +,C D 9 0 +,C D 7 3 +,a n d
CD105+. Their proportion was then calculated in freshly digested placenta specimens and fetal membranes form 3 diﬀerent donors. MSCs
represented 15.67% (±0.29%) and 2.14% (±0.65%) of cells isolated from the membrane and placenta, respectively (∗∗P = 9.25 ·10
−4). (b)
Day 1 phase contrast microscopy of adherent cells from placenta and membrane directly plated after tissue digestion in MSCs media. We
can see signiﬁcantly more adherent cells from digested membrane compared to placenta. (c) MSCs derived from placenta and membranes
were expanded up to passage 15 without changes of their morphology or proliferation rate. Proliferation rate was assessed by cell counting
at diﬀerent passages. It was similar in placenta- and membrane-derived MSCs with no diﬀerences between early and late passages. However,
proliferation rate was signiﬁcantly higher than proliferation rate of bone-marrow-derived MSCs.Stem Cells International 7
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Figure 2: The Cell analysis strategy allows the isolation of 4 diﬀerent cell populations. Cells were stained with mouse anti human CD45-
Amcyan,CD34-FITC,CD29-APC-CY7,CD90-AF700,CD73-PE,CD105-AF647.AfterFSC-A/SSC-Aselection,onlyCD45− andCD34− cells
were considered. CD73, CD105, CD90, and CD29 proﬁles were then analyzed. CD73+ CD105+ cells were more than 85% to 98% positive
for CD90 and CD29 (lower panel). However, CD90+ CD29+ represented a more heterogenous population when looking at CD73, CD105
stainings. We deﬁned diﬀerent cell populations based on CD90 and CD29 subpopulation: CD90+ CD29+;C D 9 0 − CD29+;C D 9 0 + CD29−;
CD90− CD29− (middle panel).
accessibility of these tissues will allow constituting clinically
relevant banking program.
In this study, we have isolated MSCs from placenta
and fetal membrane using very simple isolation technique
with the same great purity yield (more than 95%) than
initial FACS sorting methods [53]. Moreover, no diﬀerence
was found between diﬀerent MSCs subpopulation of pla-
centaand membrane considering phenotypic characteristics,
growth kinetic, markers expression, diﬀerentiation assays,
and transcriptomic proﬁle. This suggests the plasticity of
certain MSC markers. We indeed illustrate that the surface
markers used for MSCs cell sorting have limited interest in
fetal mesenchymal stem cell tissues isolation. We demon-
strate that the yield of MSCs retrieval is 6–8 fold superior
in the fetal membranes than in placenta. In addition,
others already demonstrated through cytogenetic analysis
that placenta-derived MSCs maintained a normal karyotype
for 30–40 passages in vitro [54]. Indeed, we demonstrate that
the Mb/Pl MSCs retain even at high number of passages
signiﬁcantly better proliferation ability than BM-MSCs.
We ﬁnally demonstrate that these fetal MSC share close
transcriptomic proﬁles with BM-MSC.
Currently, bone morphogenetic protein-2 and -7 (BMP-
2 and -7) are the only biologic modiﬁers that have received
the United States Food and Drug Administration (US-FDA)
approval for clinical applications in orthopedic surgery. The
BMPs low biologic activity is demonstrated by the doses of
tens of milligrams of commercial BMP-2- and -7-containing8 Stem Cells International
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Figure 3: Diﬀerentiation assay of Pl/Mb-MSCs in comparison to BM-MSCs and cytokines expression. (a) Representative diﬀerentiation
of Pl/Mb-MSCs passage 4 is shown. Cells were kept in induction medium (diﬀerentiation) or control standard medium (control). (a–d)
Osteogenic and adipocyte diﬀerentiation and control for BM-MSCs. (f–h) Osteogenic and adipocyte diﬀerentiation and control for Mb-
MSCs. (b) Cytokine expressions of Mb-MSCs and BM-MSCs using the proteome proﬁler. (c) Quantiﬁcation of cytokine optical density.
Measurements were obtained with image J software (NIH).Stem Cells International 9
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Figure 4: PCA representation of transcriptomic comparison of Pl-MSCs, Mb-MSCs and BM-MSCs and ingenuity pathways analysis. (a)
Mb-MSCs (red) and Pl-MSCs (green) are overlapping clearly indicating the impossibility to diﬀerentiate these MSCs at a transcriptional
level. They can clearly be diﬀerentiated from bone marrow MSCs (blue). (b) The PCA overlapping between every cell sorted sub-population
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MSCs subpopulation at a transcriptional level. (d) Ingenuity pathway analysis was able to deﬁne enriched pathways implicated in embryonic
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osteogenic diﬀerentiation with OA compared to control (without OA) after 21 days in Mb-MSCs and BM-MSCs. (b) Quantiﬁcation of
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p r o d u c t s ,w h e r e a sB M P sc o n c e n t r a t i o n sin vivo are around
several micrograms per kilogram of bone [55, 56]. BMP
therapeutic doses in preclinical and clinical trials varied by
factors up to 100 folds, demonstrating low consistency on
bone repair [57].
Noteworthy, we have characterized the mesenchymal
stem cells by the criteria used by the ISCT [33]. We would
like to point a limitation emphasized by the plasticity of
the phenotypic markers. First, the true stemness ablity (self-
renewal) of our MSCs was not demonstrated and should be
further documented in studies looking at clonality of the cell
lines. Therefore, while they have a real ability to diﬀerentiate
in diﬀerent lineage, it is impossible to say if a single cell can
indeed diﬀerentiate in diﬀerent lineages. Moreover, the role
of this cell types in vivo remains still not clearly deﬁne by lack
of speciﬁc targeting of the mesenchymal stem cells.
We recently demonstrated that OA acts downstream of
BMP-2, and our results indicate that OA may have similar
osteoinductive eﬀects to BMP-2 in mice.
We investigated the response of fetal MSCs to OA
as compared to BM-MSCs. We demonstrate that OA can
induce osteogenic diﬀerentiation in human MSCs. More
interestingly, fetal-derived MSCs display better response
to OA than BM-MSCs. We ﬁnally demonstrate that OA
can also be used as a complement for osteogenic-induced
diﬀerentiation with fetal MSCs. Finally, in accordance with
the literature, we document that the induction of osteogenic
diﬀerentiation following OA stimulation involved ERK1/2
pathway activation.
Considering that MSCs are way more abundant in
membrane compared to placenta, we, therefore, stand that
fetal membranes could be used to build MSCs bankingStem Cells International 11
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Figure 6: Phosphokinase array analysis 4h after osteoactivin stimulation. After 4h of OA stimulation, cells were harvested and protein
extracts analyzed with the human Phosphokinase array from R&D system. (a) Phosphokinase proﬁle in Pl-MSCs and BM-MSCs using the
proteome proﬁler. (b) Quantiﬁcation of phosphokinase optical density. Measurements were obtained with image J software (NIH). ERK2 is
activated in placental MSCs when submitted to osteoactivin stimulation.
program in order to meet clinical threshold in bone fracture
reparation. Isolation of Mb-MSCs through selective culture
in DMEM-low glucose supplemented with 20% serum and
antibiotics seems to be the most eﬃcient process. This
process is very adapted for automation compatible with large
cell banking programs.
Moreover, the increased capacity of response to osteo-
genicdiﬀerentiationuponosteoactivintreatmentpromptsus
to study the role of fetal membrane MSCs in experimental
preclinical model of bone regeneration. Indeed, critical
animal studies would be necessary to determine how MSCs
are recruited and survive at the fracture site, their repair
eﬀectiveness, and the mechanisms through which they exert
their actions.
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